New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 400mg - powder for injection with diluent - 100 mg/ml - active: sodium valproate 400mg excipient: water for injection - epilim iv: the treatment of patients with epilepsy or bipolar disorder, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Iżrael - Ingliż - Ministry of Health

teva pharmaceutical industries ltd, israel - dipyrone - tablets - dipyrone 500 mg - metamizole sodium - metamizole sodium - relief of moderate to severe pain as in headache, toothache, dysmenorrhea andfor high fever that does not respond to other measures.

Iżrael - Ingliż - Ministry of Health

teva israel ltd - dipyrone - caplets - dipyrone 500 mg - metamizole sodium - metamizole sodium - relief of moderate to severe pain as in headache, toothache, dysmenorrhea andfor high fever that does not respond to other measures.

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dechra regulatory b.v. - butylhyoscine bromide 4 mg/ml - eq. hyoscine 2,76 mg/ml; metamizole sodium monohydrate 500 mg/ml - eq. noramidopyrine 443 mg/ml - solution for injection - 500 mg/ml - 4 mg/ml - metamizole sodium monohydrate 500 mg/ml; butylhyoscine bromide 4 mg/ml - butylscopolamine and analgesics - horse; dog; pig; cattle

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 40 mg/ml - syrup - 200 mg/5ml - active: sodium valproate 40 mg/ml excipient: cherry flavour 17.40.0740 ponceau 4r purified water saccharin sodium sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate sorbitol sucrose - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 100mg - tablet - 100 mg - active: sodium valproate 100mg excipient: hydrated silica light kaolin magnesium stearate maize starch purified water - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.